智通财经APP讯，大成生化科技(00809)发布公告，本集团预期将于截至2025年12月31日本年度录得净收益(扣除税项影响前)，范围约在1亿港元至3亿港元，远低于本集团截至2024年12月31日止年度(去年同期)录得的净收益(扣除税项影响前)约7.46亿港元。
另一方面，本集团预期录得收入及毛利分别增加约13.9%及2.8%，由去年同期的约 20.01亿港元及1.91亿港元增至本年度的约22.79亿港元及1.96亿港元。然而，本年度毛利率预期与去年同期的9.5%相比，将降至8.6%。
本年度毛利率及净收益(扣除税项影响前)预期下降主要归因于以下因素：自2025年年中起，国内玉米颗粒价格上涨导致本集团的经营成本增加;及欧洲联盟对中国内地赖氨酸发起反倾销调查引致国内市场赖氨酸产品供过于求，两者均对本集团的毛利率造成不利影响;及在2024年12月30日完成出售本公司八间附属公司后，未确认一次性收益约 19.62亿港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.